NAFLD/NASH is Not Just A 'western' on Problem: Some Perspectives on NAFLD/NASH from the East

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 218-228

  Chitturi, Shivakumar ^a   George, Jacob ^b  

^a University of Sydney ^*  (India)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Insulin resistance; Metabolic disorder; Nonalcoholic fatty liver disease (NAFLD); Obesity; Pathogenesis

Indexed keywords

EID: 85031812877     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch18     Document Type: Chapter

References (52)

1. Clark JM, Brancati FL, Diehl AM. Non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
2. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y, Kosaka K. Health risks among Japanese men with moderate body mass index. Int J Obese Relat Metab Disord 2000; 24: 358-62.
3. Younossi ZM, Diehl AM, Ong JP. Non-alcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52.
4. Hasan I, Gani RA, Machmud R et al. Prevalence and risk factors for non-alcoholic fatty liver in Indonesia. J Gastroenterol Hepatol 2002; 17 (Suppl.): A30.
5. Nomura H, Kashiwagi S, Hayashi J et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-9.
6. Oshibuchi M, Nishi F, Sato M, Ohtake H, Okuda K. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J Gastroenterol Hepatol 1991; 6: 165-8.
7. Akahoshi M, Amasaki Y, Soda M et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001; 24: 337-43.
8. Omagari KH, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1089-105.
9. Lai SW, Tan CK, Ng KC. Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 2002; 95: 1288-92.
10. International Diabetes Institute. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia, 2000.
11. Leung NWY, Tsang TWC, Liew CT, Tomlinson B. Nonalcoholic steatohepatitis (NASH) in0 Hong Kong: role of hepatologist in the diagnosis of diabetes mellitus. Abstracts of World Congress of Gastroenterology, Vienna, 1998.
12. Agarwal SR, Malhotra V, Sakhuja P, Sarin SK. Clinical, biochemical and histological profile of non-alcoholic steatohepatitis. Indian J Gastroenterol 2001; 20: 183-6.
13. Amarapurkar DN, Amarapurkar AD. Non-alcoholic steatohepatitis: clinicopathological profile. J Assoc Physicians India 2000; 48: 311-3.
14. Park J, Kim MK, Kim SJ et al. Clinical predictors reflecting the pathologic grade of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver: Korean cases different from western patients. Hepatology 2000; 32: 419A.
15. Janaki S, Hewavisenthi S. Profile of non-alcoholic steato- hepatitis in a Sri Lankan population. J Gastroenterol Hepatol2001; 16 (Suppl.): A81.
16. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
17. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepato- logy 2002; 35: 373-9.
18. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003; 18: 124-38.
19. Fall CHD. Non-industrialised countries and affluence. J R Soc Med 2001; 60: 33-50.
20. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-31.
21. Sekikawa A, Tominaga M, Takahashi K et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care 1993; 16: 570-4.
22. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
23. Hara H, Egusa G, Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract 1994; 24 (Suppl.): S37-42.
24. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
25. Shirai K, Shinomiya M, Saito Y et al. Incidence of childhood obesity over the last 10 years in Japan. Diabetes Res Clin Pract 1990; 10 (Suppl. 1): S65-70.
26. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 1998; 37: 111-5.
27. Tominaga K, Kurata JH, Chen YK et al. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-9.
28. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997; 24: 317-21.
29. Chitturi S, Farrell GC, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
30. Tobe K, Ogura T, Tsukamoto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am J Gastroenterol 1999; 94: 3328-35.
31. Nakao K, Nakata K, Ohtsubo N et al. Association between non-alcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002; 97: 1796-801.
32. Seki S, Kitada T, Yamada T et al. In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
33. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J Hepatol 2003; 38: 32-8.
34. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-p1 level and efficacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
35. Iwamoto N, Ogawa Y, Kajihara S et al. Gln27Glu p2-adrenergic receptor variant is associated with hyper-triglyceridemia and the development of fatty liver. Clin Chim Acta 2001; 314: 85-91.
36. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in non-alcoholic steato- hepatitis. Hepatology 2002; 35: 898-904.
37. Lee DM, Mun BS, Ahn HS et al. Relation of apolipo- protein E polymorphism to clinically diagnosed fatty liver disease [in Korean]. Taehan Kan Hakhoe Chi 2002; 8: 355-62.
38. Park J, Kim MK, Jung G et al. Expression of Kupffer cells and uncoupling protein 2 in the liver of patients with non-alcoholic steatohepatitis: difference and similarity to alcoholic hepatitis. Hepatology 2000; 34: 423A.
39. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-60.
40. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Non-alcoholic steatohepatitis: risk factors for liver fibrosis. Hepatology Res 2002; 24: 429-38.
41. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
42. Chitturi C, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific associations of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-8.
43. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of non-alcoholic steatohepatitis?. Gastroenterology 2002; 123: 375-8.
44. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
45. Cotrim HP, Parana R, Braga E, Lyra L. Non-alcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000; 95: 3018-9.
46. Zen Y, Katayanagi K, Tsuneyama K et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001; 51: 127-31.
47. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
48. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995; 10: 414-21.
49. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight changes on serum transaminase activities in obese children. Acta Paediatr Jpn 1997; 39: 210-4.
50. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
51. Jackson A, Cole C, Esquiro J, Edwards M. Obesity in primary care patients in Kelantan, Malaysia: prevalence, and patients' knowledge and attitudes. Southeast Asian J Trop Med Public Health 1996; 27: 776-9.
52. Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-5.